Destabilisation of dimeric 14-3-3 proteins as a novel approach to anti-cancer therapeutics

Oncotarget

Volumn 6, Issue 16, 2015, Pages 14522-14536

  Woodcock, Joanna M ^a   Coolen, Carl ^a   Goodwin, Katy L ^a   Baek, Dong Jae ^b   Bittman, Robert ^b   Samuel, Michael S ^a,c   Pitson, Stuart M ^a,c   Lopez, Angel F ^a,c  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Apoptosis; Biochemistry; Signal transduction; Small molecules; Sphingosine

Indexed keywords

ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN 14 3 3; PROTEIN KINASE B; RAF PROTEIN; RB 011; RB 012; UNCLASSIFIED DRUG; SPHINGOSINE;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; FEMALE; MITOCHONDRION; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; SPHINGOLIPID METABOLISM; XENOGRAFT; ANIMAL; GENETICS; HUMAN; JURKAT CELL LINE; LUNG TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

14-3-3 PROTEINS; ANIMALS; APOPTOSIS; HUMANS; JURKAT CELLS; LUNG NEOPLASMS; MICE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84931070847     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3995     Document Type: Article

References (43)

1. Porter GW, Khuri FR and Fu H. Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Sem Cancer Biol 2006; 16: 193-202.
2. Morrison D. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends in Cell Biol 2008; 19: 16-23.
3. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
4. Fan T, Li R, Todd NW, Qiu Q, Fang H-B, Wang H, Shen J, Zhao RY, Caraway NP, Katz RL, Stass SA and Jiang F. Up-regulation of 14-3-3ζ in lung cancer and its implication as prognostic and therapeutic target. Cancer Res 2007; 67: 7901-7906.
5. Matta A, DeSouza LV, Ralhan R and Siu KWM. Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry. J. Proteome Res 2008; 7: 2078-2087.
6. Hodgkinson VC, Agarwal V, ELFadl D, Fox JN, McManus PN, Mahapatra TK, Kneeshaw PJ, Drew PJ, Lind MJ and Cawkwell L. Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in EF-positive breast cancer. J Proteomics 2012; 75: 2745-2752.
7. He Y, Wu X, Liu X, Yan G, Xu C. LC-MS/MS analysis of ovarian cancer metastasis-related proteins using a nude mouse model: 14-3-3ζ as a candidate biomarker. J Proteome Res 2010; 9: 6180-6190.
8. Neal CL and Yu D. 14-3-3ζ as a prognostic marker and therapeutic target for cancer. Expert Opin Ther Targets 2010; 14: 1343-1354.
9. Radhakrishnan VM and Martinez JD. 14-3-3ζ induces oncogenic transformation by stimulating MAP kinase and PI3K signaling. PLOS One. 2010; 5: e11433.
10. Matta A, DeSouza LV, Ralhan R and Siu KWM. Small interfering RNA targeting 14-3-3ζ increases efficacy of chemotherapeutic agents in head and neck cancer cells. Mol Cancer Ther 2010; 9: 2676-2688.
11. Li Z, Zhao J, Du Y, Park HR, Sun S-Y, Bernal-Mizrachi L, Aitken A, Khuri FR and Fu H. Down-regulation of 14-3-3ζ suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Nat Acad Sci 2008; 105: 162-167.
12. Zhao J, Meyerkord CL, Du Y, Khuri FR and Fu H. 14-3-3 proteins as potential therapeutic targets. Sem Cell & Dev Biol 2012; 22: 706-712.
13. Corradi V, Mancini M, Manetti F, Petta S, Santucci MA and Botta M. Identification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. Bioorg & Med Chem Letts 2010; 20: 6133-6737.
14. Zhao J, Du Y, Horton JR, Upadhyay AK, Lou B, Bai Y, Zhang X, Du L, Li M, Wang B, Zhang L, Barbieri JT, Khuri FR et al. Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor. Proc Natl Acad Sci USA 2011; 108: 16212-16216.
15. Woodcock JM, Ma Y, Coolen C, Pham D, Jones C, Lopez AF and Pitson SM. Sphingosine and FTY720 directly bind pro-survival 14-3-3 proteins to regulate their function. Cell Signaling 2010; 22: 1291-1299.
16. Messaritou G, Grammenoudi S and Skoulakis EMC. Dimerization is essential for 14-3-3ζ stability and function in vivo. J Biol Chem 2010; 285: 1692-1700.
17. Woodcock JM, Murphy J, Stomski FC, Berndt MC and Lopez AF. The dimeric versus monomeric status of 14-3-3ζ is controlled by phosphorylation of Ser58 at the dimer interface. J Biol Chem 2003; 278: 36323-36327.
18. Ma Y, Pitson S, Hercus T, Murphy J, Lopez A and Woodcock J. Sphingosine activates protein kinase A type II by a novel cAMP-independent mechanism. J Biol Chem 2005; 280: 26011-26017.
19. Powell DW, Rane MJ, Joughin BA, Kalmukova R, Hong J-H, Tidor B, Dean WL, Pierce WM, Klein JB, Yaffe MB and McLeish KR. Proteomic identification of 14-3-3ζ as a mitogen-activated protein kinase-activated protein kinase 2 substrate: role in dimer formation and ligand binding. Mol Cell Biol 2003; 23: 5376-5387.
20. Hamaguchi A, Suzuki E, Murayama K, Fujimura T, Hikita T, Iwabuchi K, Handa K, Withers DA, Masters SC, Fu H and Hakomori S. Sphingosine-dependent protein kinase-1, directed to 14-3-3, is identified as the kinase domain of protein kinase C delta. J Biol Chem 2003; 278: 41557-41565.
21. Pitman MR, Woodcock JM, Lopez AF and Pitson SM. Molecular targets of FTY720 (Fingolimod). Curr Mol Med 2012; 12: 1207-1219.
22. Baek DJ, MacRitchie N, Pyne NJ, Pyne S and Bittman R. Synthesis of selective inhibitors of sphingosine kinase 1. Chem Commun 2013; 49: 2136-2138.
23. Ibbetson SJ, Lyne NT, Pollard AN, Olson MF and Samuel MS. Mechanotransduction pathways promoting tumor progression are activated in invasive human squamous cell carcinoma. Am. J. Pathol. 2013; 183: 930-937.
24. Samuel MS, Lopez JI, McGhee EJ, Croft DR, Strachan D, Timpson P, Munro J, Schroder E, Zhou J, Brunton VG, Barker N, Clevers H, Sansom OJ et al. Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell 2011; 19: 776-791.
25. Yu L, Lu T, Luan Y-X, Liu J and Xu G-Y. Studies on the effects of amino acids on micellization of CTAB via surface tension measurements. Colloids and Surfaces A: Physicochem. Eng. Aspects 2005; 257: 375-379.
26. Nozaki Y, Reynolds JA and Tanford A. The interaction of a cationic detergent with bovine serum albumin and other protein. J Biol Chem 1974; 249: 4452-4459.
27. Fujino M, Li X-K, Kitazawa Y, Guo L, Kawasaki M, Funeshima N, Amano T and Suzuki S. Distinct pathways of apoptosis triggered by FTY720, etoposide, and anti-Fas antibody in human T-lymphoma cell line (Jurkat cells). J Pharm and Exp Therapeutics 2002; 300: 939-945.
28. Kuzelova K, Grebenova D, Pluskalova M, Kavan D, Halada P and Hrkal Z. Isoform-specific cleavage of 14-3-3 proteins in apoptotic JURL-MK1 cells. J Cell Biochem 2009; 106: 673-681.
29. Slee EA, Keogh SA and Martin SJ. Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death and Diff 2000; 7: 556-565.
30. Wallington-Beddoe CT, Don AS, Hewson J, Qiao Q, Papa RA, Lock RB, Bradstock KF and Bendall LJ. Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia. PLoS One e36429.
31. Saddoughi S, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, Senkal CE, Garrett-Mayer E, De Palma RM et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumor suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Molecular Medicine 2013; 5: 105-121.
32. Ottmann C. Small molecule modulators of 14-3-3 protein-protein interactions. Bioorg and Med Chem 2012; 21: 4058-4062.
33. Ito E, Yip KE, Katz D, Fonseca SB, Hedley DW, Chow S, Xu GW, Wood TE, Bastianutto C, Schimmer AD, Kelley SO and Liu FF. Potential use of cetrimonium brminde as an apoptosis promoting anticancer agent for head and neck cancer. Mol Pharm 2009; 76: 969-983.
34. Xing H, Zhang S, Weinheimer C, Kovacs A and Muslin AJ. 14-3-3 proteins block apoptosis and differentially regulate MAPK cascades. EMBO J 2000; 19: 349-358.
35. Zhang L, Chen J and Fu H. Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. Proc Natl Acad Sci USA 1999; 96: 8511-8515.
36. Tzivion G, Luo Z and Avruch J. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 1998; 394: 88-92.
37. Zhou J, Shao Z, Kerkela R, Ichijo H, Muslin AJ, Pombo C, Force T. Serine 58 of 14-3-3ζ is a molecular switch regulating ASK1 and oxidant stress-induced cell death. Mol Cell Biol 2009; 29: 4167-4176.
38. Matitau AE, Gabor TV, Gill RM and Scheid MP. MEKK2 kinase association with 14-3-3 protein regulates activation of c-Jun N-terminal kinase. J Biol Chem 2013; 299: 28293-28302.
39. Neal CL, Xu J, Li P, Mori S, Yang J, Neal NN, Zhou X, Wyszomierski SL and Yu D. Overexpression of 14-3-3ζ in cancer cells activates PI3K via binding the p85 regulatory subunit. Oncogene 2011; 31: 897-906.
40. Takihara Y, Matsuda Y and Hara J. Role of the β isoform of 14-3-3 proteins in cellular proliferation and oncogenic transformation. Carcinogenesis 2000; 21: 2073-2077.
41. Rehman SK, Li S-H, Wzszomierski SL, Wang Q, Li P. Sahin O, Xiao Y, Zhang S, Xiong Y, Yang J, Wang H, Guo H, Zhang JD et al. 14-3-3ζ orchestrates mammary tumor onset and progression via miR-221-mediated cell proliferation. Cancer Res 2013; 74: 363-373.
42. Bergamaschi A and Katzenellenbogen BS. Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. Oncogene 2012; 31: 39-47.
43. Bian H-B, Pan X, Yang J-S, Wang Z-X and De W. Up-regulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res 2011; 30: 20.